NAD+

07NAD+ IV Therapy: Evidence and Pharmacokinetics

Core thesis: NAD+ is a central redox cofactor and signaling substrate whose tissue pools decline with age, inflammation, metabolic dysfunction, and high NAD-consuming enzyme activity. IV NAD+ therapy is marketed as a rapid way to restore cellular energy, detoxification capacity, cognition, and addiction recovery. The mechanistic rationale is real; the direct human evidence for IV NAD+ clinical outcomes is still early, mostly uncontrolled, and weaker than evidence that oral NAD+ precursors such as NR and NMN reliably shift the NAD metabolome.

Bottom line: treat IV NAD+ as an experimental, high-cost pharmacologic intervention, not a proven longevity therapy. It may be useful when a supervised clinic wants acute, observable physiologic effects or when oral precursor response is poor, but it should be compared against cheaper and better-studied options: Exercise Science and Longevity, circadian correction, Mitochondrial Health protocols, niacin/NR/NMN, and reduction of inflammatory NAD drains.

Evidence at a Glance

Swipe table →

The most useful skeptical framing comes from Radenkovic, Reason, and Verdin's PRISMA-style review of NAD therapeutics: NAD pharmacology is promising and appears relatively safe, but human trials are heterogeneous, many indications have only one small study, and direct comparisons against exercise/diet are still needed (PMID: 32942582).

Redox Currency

NAD exists mostly as a redox pair:

• NAD+ — oxidized electron acceptor
• NADH — reduced electron donor

The NAD+/NADH ratio is a proxy for cellular redox state. A high-energy, insulin-sensitive cell can flexibly move electrons through glycolysis, the TCA cycle, beta-oxidation, and oxidative phosphorylation. A metabolically impaired cell may have altered NAD+/NADH balance, mitochondrial bottlenecks, excess ROS, and poor substrate switching.

NAD-Consuming Enzymes

NAD+ is also consumed by signaling enzymes:

• Sirtuins — deacetylases linked to mitochondrial biogenesis, circadian rhythm, DNA repair, and stress resistance. See NAD+ and Sirtuin Activators.
• PARPs — DNA-damage sensors and repair enzymes. Chronic DNA damage can drain NAD+.
• CD38/CD157 — ectoenzymes that degrade NAD+ and rise with inflammatory/aging phenotypes.
• SARM1 — axonal degeneration mediator; relevant to neurodegeneration and injury.

This creates a first-principles model: NAD+ falls not merely because less is produced, but because aging tissues often have higher demand from inflammation, DNA damage, immune activation, circadian disruption, and mitochondrial inefficiency.

NAD Salvage Pathway

The dominant pathway in many tissues is salvage from nicotinamide:

1. Nicotinamide (NAM)
2. NAMPT converts NAM → NMN
3. NMNAT converts NMN → NAD+

NR enters via conversion to NMN; NMN enters near the end of the pathway. Niacin enters through the Preiss–Handler pathway. Tryptophan can synthesize NAD de novo through the kynurenine pathway, but this route is metabolically costly and inflammation-sensitive.

Clinical implication: giving NAD+ directly may not bypass all bottlenecks. Extracellular NAD+ can be rapidly degraded into NAM, NMN, NR, ADPR, and methylated metabolites. The therapeutic question is whether IV NAD+ produces a superior intracellular NAD signal compared with precursors — not whether NAD+ itself is important.

The Commercial Claim

IV clinics often claim that direct NAD+ infusion bypasses digestion and produces near-100% bioavailability. This is only partly meaningful. The compound enters blood, but the relevant target is intracellular NAD pools in specific tissues, especially brain, skeletal muscle, liver, immune cells, and pancreatic beta cells.

What Pilot Pharmacokinetic Work Suggests

Small human infusion studies suggest infused NAD+ is rapidly metabolized. Plasma NAD+ may not simply rise in proportion to the dose; downstream metabolites such as nicotinamide, methyl-nicotinamide, ADPR, and urinary NAD-related products increase. This supports the idea that IV NAD+ acts partly as a high-dose substrate pulse into extracellular degradation and salvage pathways rather than as intact NAD+ directly entering cells.

A 2026 Frontiers in Aging retrospective pilot study compared commercial IV NAD+ vs IV NR in 14 real-world clients. It found:

• IV NR was better tolerated than IV NAD+.
• NAD+ IV produced moderate-to-severe GI symptoms, increased heart rate, chest pressure, throat/chest symptoms, and longer infusion times.
• NR IV produced mostly mild tingling/cramping and shorter infusion times.
• No short-term signal in ALT, AST, hsCRP, BUN/creatinine, TSH, or blood pressure.
• The study had major limitations: retrospective design, n=14, no placebo arm, commercial clinic setting, and authors employed by the clinic/provider ecosystem.

Interpretation: IV NAD+ clearly has physiologic effects during infusion. It is not yet proven that those effects translate into better mitochondrial, cognitive, addiction, or longevity outcomes than oral precursor therapy.

1. Addiction and Withdrawal Support

This is the oldest use case in integrative practice. Protocols descend from mid-20th-century observations and modern commercial detox clinics.

Swipe table →

Mechanistic plausibility includes mitochondrial support, redox correction, neurotransmitter synthesis support, and reduction of oxidative stress. But addiction outcomes are multifactorial: trauma, environment, sleep, nutrition, social structure, psychiatric comorbidity, and pharmacologic stabilization usually dominate.

Practical conclusion: IV NAD+ may be considered an adjunct in supervised addiction medicine, not a standalone detox cure. It should not replace evidence-based alcohol/benzodiazepine withdrawal management where seizures, delirium tremens, or autonomic instability are risks.

2. Metabolic Health and Insulin Sensitivity

The strongest human signal for an NAD precursor is not IV NAD+ but oral NMN. Yoshino et al. performed a 10-week randomized, double-blind, placebo-controlled trial of 250 mg/day NMN in overweight/obese postmenopausal women with prediabetes. NMN increased skeletal muscle insulin signaling and insulin-stimulated glucose disposal measured by clamp methods (PMID: 33888596).

This is a useful anchor because it measured a hard metabolic physiology endpoint, not only subjective energy. However:

• n was small: 25 completers.
• Population was narrow: postmenopausal women with prediabetes and overweight/obesity.
• It does not prove benefit in men, lean people, athletes, or healthy longevity users.
• It does not prove IV NAD+ is superior to oral NMN.

3. Neurodegeneration, MCI, and Brain NAD+

NR trials show that blood NAD+ can rise in older adults and some neurologic cohorts. A randomized placebo-controlled NR trial in older adults with mild cognitive impairment reported increased blood NAD+ but no clear cognition change over the short trial window (PMID: 37994989).

A skeptical first-principles view: raising blood NAD is necessary but not sufficient. Brain outcomes depend on transport, cell-type-specific metabolism, neuroinflammation, sleep, vascular perfusion, glymphatic clearance, glucose/ketone metabolism, and amyloid/tau/alpha-synuclein context. See Sleep Optimization, Mitochondrial Health, and Metabolic Health and Insulin.

4. Chronic Fatigue, Lyme, and Post-Infectious Syndromes

IV NAD+ is often marketed for chronic fatigue, chronic Lyme, long-COVID-like syndromes, and post-infectious malaise. Plausibility comes from mitochondrial dysfunction, immune activation, oxidative stress, and autonomic imbalance.

Evidence remains mostly anecdotal. Patients may report dramatic acute energy changes, but without controlled designs it is difficult to separate NAD effects from hydration, magnesium, B vitamins, placebo/context effects, rest, improved sleep after treatment, or regression to the mean.

For biofilm/chronic infection contexts, avoid assuming fatigue is merely an NAD deficiency. Look for persistent immune triggers, sinus/gut biofilms, mycotoxin load, dysautonomia, iron dysregulation, sleep apnea, nutrient deficiencies, and endocrine issues. Related: Biofilms and Chronic Infections, Lyme and Co-infections, Mitochondrial Health.

5. General Longevity and Performance

The direct longevity claim is the weakest. NAD+ biology sits upstream of many aging pathways, but there is no human evidence that intermittent IV NAD+ extends lifespan or meaningfully slows biological aging. Biomarker improvements are not the same as mortality or healthspan outcomes.

A rational longevity stack would place IV NAD+ behind:

1. Sleep/circadian correction
2. Resistance training + Zone 2
3. Protein and micronutrient adequacy
4. Metabolic health and visceral fat reduction
5. Sauna/thermal hormesis if tolerated
6. Oral NAD precursor or niacin-family experiment with labs
7. IV NAD+ only if there is a clear hypothesis, objective tracking, and medical supervision

Oral Precursors vs IV NAD+

Swipe table →

NR Evidence Snapshot

Airhart et al. showed oral NR changed the blood NAD metabolome in healthy volunteers (PMID: 29211728). Later trials found NR generally tolerable at commonly studied doses, including higher-dose short-term safety work, but clinical effects vary by population and endpoint.

NMN Evidence Snapshot

NMN has human data for safety and metabolic signaling, including the Yoshino prediabetes trial (PMID: 33888596). As with NR, the evidence supports metabolome modulation more strongly than broad anti-aging outcomes.

Niacin / Nicotinic Acid

Niacin is cheap, old, and potent but produces flushing and has different pharmacology. It is under-discussed in longevity circles because it lacks the supplement-market glamour of NR/NMN. It should be evaluated separately, particularly for lipid effects, flushing tolerance, glucose effects, liver monitoring at high doses, and methylation dynamics.

Before Starting

Swipe table →

After a Trial

Re-check objective endpoints at 4–8 weeks:

• Symptoms: energy, sleep, cognitive clarity, cravings, exercise recovery
• Wearables: HRV, resting HR, sleep architecture trends
• Labs: HbA1c if metabolic target; liver/kidney markers if repeated IVs; homocysteine if high-dose precursors
• Performance: Zone 2 power/pace at fixed HR; grip strength; reaction time; cognitive task consistency

Avoid: declaring success after one euphoric post-infusion day. Hydration, attention, expectation, and acute sympathetic shifts can all feel like a breakthrough.

Uses

These are common real-world patterns, not evidence-established optimal dosing.

Swipe table →

Infusion Rate

Many adverse symptoms are rate-dependent. Slower is usually better tolerated.

Common symptoms during NAD+ infusion:

• Nausea or abdominal tightness
• Chest pressure or throat tightness
• Warmth/flushing
• Headache
• Anxiety-like sympathetic activation
• Muscle cramping
• Metallic or unusual taste

Rate response: pause or slow the drip if symptoms appear. Severe chest pain, dyspnea, syncope, allergic symptoms, or abnormal vitals require medical evaluation, not “pushing through.”

Cofactors Often Used

Swipe table →

Methylation Consideration

High NAD precursor use can increase nicotinamide turnover and methylated metabolites. In sensitive patients, monitor or consider:

• Homocysteine
• Folate/B12 status
• Riboflavin/B2 status
• Glycine intake
• Choline/betaine intake

Do not assume methyl donors are universally beneficial. Some people become anxious, insomniac, or irritable when methylation support is pushed too hard.

Contraindications and Cautions

• Pregnancy or breastfeeding: insufficient evidence
• Active cancer: theoretical concern because rapidly dividing cells use NAD metabolism; oncology supervision required
• Severe kidney disease: altered clearance and electrolyte risk
• Severe liver disease: metabolite handling concerns
• Uncontrolled hypertension or unstable cardiovascular disease: infusion symptoms may mimic or worsen cardiopulmonary stress
• Complex psychiatric instability: acute activation may worsen anxiety/insomnia
• Active alcohol/benzodiazepine withdrawal: requires conventional medical withdrawal management

When IV NAD+ Is More Defensible

• Clear clinical hypothesis: withdrawal support, severe fatigue trial, poor oral response, supervised mitochondrial protocol
• Objective baseline and follow-up measures
• Practitioner can explain dose, infusion rate, cofactors, adverse event handling, sterile compounding source
• Patient has already corrected obvious foundations: sleep, food quality, protein, magnesium, sunlight/circadian cues, training load
• Limited trial window with stop criteria

When IV NAD+ Is Probably Low-Value

• “Longevity” marketing with no endpoints
• Clinic sells expensive subscription packages before a response is known
• No medical history review or medication interaction review
• Patient expects IV NAD+ to compensate for sleep deprivation, alcohol, overtraining, or uncontrolled metabolic disease
• No willingness to compare against cheaper oral NR/NMN/niacin experiments

Stop Criteria

Stop or reassess if:

• No measurable benefit after 3–6 sessions
• Symptoms worsen, especially insomnia, anxiety, palpitations, chest pressure, or migraines
• Liver/kidney markers worsen
• The protocol becomes financially burdensome without clear outcomes
• Benefits last only hours and do not compound into functional improvement

Open Questions and Contradictions

1. Does intact NAD+ enter human cells meaningfully after IV infusion, or is the effect mostly through extracellular degradation into NAM/NR/NMN/ADPR?
2. Is IV NR or IV NMN better tolerated and more biologically efficient than IV NAD+? Early commercial data suggest IV NR may be better tolerated, but evidence is tiny and conflicted.
3. Which tissue matters? Blood NAD may rise while brain, skeletal muscle, liver, and immune-cell responses diverge.
4. What is the optimal pulse schedule? Continuous high NAD precursor exposure may not mimic hormetic biology.
5. Could chronic high-dose NAD repletion support cancer cell metabolism in some contexts? This is biologically plausible but not clinically resolved.
6. How should NAD repletion interact with Metformin and Rapamycin, fasting, sauna, exercise, and mitochondrial stressors? Timing may matter.
7. Are benefits strongest in deficient/dysregulated states? Likely yes. Healthy optimizers may show weaker clinical returns.

Notes

• [ ] Add a dedicated comparison note for niacin vs NR vs NMN vs NADH vs IV NAD+.
• [ ] Track emerging IV NAD+/IV NR trials separately from oral precursor trials.
• [ ] Look for patents and older addiction-medicine records behind the Hitt/Braverman NAD detox lineage.
• [ ] Investigate whether CD38 inhibition plus precursor therapy has better mechanistic leverage than high-dose IV NAD+ alone.
• [ ] Add adverse-event reports if pharmacovigilance signals appear.

08NAD+ Precursor Market in Crisis — Nature Metabolism Evidence Correction

Overview

A May 2026 Nature Metabolism study (Trętowicz et al.) challenged the foundational claim that blood NAD+ levels universally decline with age — the premise underlying the entire NAD+ precursor supplement market (NMN, NR, nicotinamide). This directly threatens brands including Bryan Johnson's Blueprint, Tru Niagen, Elysium Basis, Thorne, and Novos. Two additional 2026 studies (Berven et al. and Christen et al.) further refined the evidence base, clarifying which precursors work, how, and in which compartments.

Trętowicz et al. — Whole-Blood NAD+ Stability (Primary Source)

• Citation: Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nature Metabolism (2026). DOI: 10.1038/s42255-026-01537-5. PMID: 42135539. Epub 2026 May 14.
• Design: Seven independent human cohorts (n > 300 total, ages 18–87). Validated mass-spectrometry assay. Multiple lifestyle interventions tested (exercise, protein supplementation).
• Core Finding: Whole-blood NAD+ levels remain remarkably stable across age and lifestyle interventions. NR supplementation increased levels 4–6 fold in responders, confirming precursors do raise blood NAD+ — but the "universal age decline" narrative is unsupported for whole blood.
• Confounders Identified: Freeze-thaw cycles and assay methodology (enzymatic vs. mass-spec) contributed to variability in prior studies claiming age-related decline.
• Critical Nuance: This study measured whole blood only. It does not address tissue-level NAD+ (muscle, liver, brain), where animal models show clear age-related depletion. Blood and tissue NAD+ are distinct compartments.

Berven et al. — NAD-Brain Pharmacokinetic Study (NR vs NMN Head-to-Head)

• Citation: Berven H, Svensen M, Eikeland H, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience. 2026;29(3):114764. PMID: 41858901.
• Design: Phase I crossover trial, 1,200 mg/day NR or NMN in healthy adults and Parkinson's disease patients. Blood NAD+ measured by LC-MS; brain NAD+ measured by ³¹P-MRS (phosphorus magnetic resonance spectroscopy).
• Key Findings:
• Blood: NR raised blood NAD+ ~2.3× more than NMN at equivalent gram doses (161% vs. 69% increase). Difference persisted after correcting for molecular weight.
• Brain: Four weeks of sustained NR supplementation raised brain NAD+ levels in healthy participants — one of the first human demonstrations of cerebral NAD+ augmentation from oral precursors. In Parkinson's patients, brain NAD+ trended upward but did not reach significance.
• Pharmacokinetics: Blood NAD+ plateaued after ~2 weeks; brain NAD+ increases became detectable only after ~4 weeks, indicating delayed tissue equilibration.
• Implication: NR may be pharmacokinetically superior to NMN for both blood and brain NAD+ augmentation. Tissue-level effects lag blood-level changes by weeks.

Christen et al. — Booster Comparison & Microbiome (Nestlé Health Science)

• Citation: Christen S, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism 2025;8:62–73. DOI: 10.1038/s42255-025-01421-8.
• Design: RCT, 67 healthy adults, 14-day supplementation: NR (1 g/day, n=17), NMN (1 g/day, n=15), nicotinamide/Nam (0.5 g/day, n=17), or placebo (n=18).
• Key Findings:
• NR and NMN both significantly raised baseline whole-blood NAD+ over 14 days; Nam did not (only acute transient effect).
• NR and NMN are not directly absorbed systemically. Instead, gut microbiota convert them to nicotinic acid (NA), which enters the Preiss-Handler pathway — a "microbiome-mediated" mechanism.
• NR and NMN also modulated gut bacteria composition and increased short-chain fatty acid (SCFA) production.
• No effect of sex or age on response.
• Implication: NR and NMN are comparably effective at raising blood NAD+ when administered chronically (contrasting with Berven's single-dose pharmacokinetic advantage for NR). The gut microbiome is a critical intermediary.

Blood vs Tissue NAD+ — The Central Distinction

Swipe table →

The preclinical benefits of NAD+ augmentation — sirtuin activation, improved mitochondrial function, enhanced DNA repair via PARP — occur at the cellular/tissue level, not in whole blood. The Trętowicz study does not invalidate the mechanistic rationale for supplementation; it invalidates the marketing claim that "blood NAD+ decline with age → supplementation corrects aging."

Competitive Intelligence — Brand & Clinic Exposure Map

Swipe table →

• High Exposure: Brands whose core marketing premise is "NAD+ declines with age → our product fixes it" using blood-level claims.
• Repositioning Options: Focus on microbiome benefits (Christen), muscle/brain NAD+ augmentation (Berven), or "optimization" rather than correction of universal decline.
• Dr. Shalender Bhasin (NPR, May 2026): Emphasized early-stage human evidence; no lifespan RCTs exist.

Claims Audit Recommendations

1. Remove or caveat "NAD+ declines with age → supplementation reverses aging" framing for blood-based claims.
2. Cite 2026 Nature Metabolism and iScience papers explicitly — these are now the methodological benchmarks.
3. Separate tiers clearly: - ✅ Supported: Blood NAD+ rises with NR/NMN supplementation (multiple RCTs). - ✅ Supported: Brain NAD+ rises with sustained NR supplementation (Berven 2026, n=small). - ⚠️ Speculative: Muscle NAD+ rises with oral precursors (animal data strong, human indirect). - ❌ Unsupported: Lifespan extension, telomere lengthening, or "anti-aging" in humans.
4. Disclose microbiome pathway: NR/NMN work partly via gut conversion to NA (Christen 2026) — relevant for patients on antibiotics or with gut dysfunction.

Wikilinks

• NAD+ Precursors and Telomere Biology - Evidence Audit
• NAD+ and Sirtuin Activators
• 11 - Longevity and Anti-Aging/NAD+ IV Therapy
• Rapamycin mTOR Inhibition - PEARL Trial Evidence
• Epitalon

09NAD+ Precursors and Telomere Biology: Evidence Review

Bottom-Line Verdict (Sept 2026)

Swipe table →

Practical Talking Points

1. "Will it raise my NAD+?" — Yes (blood), via direct and microbiome-mediated pathways. Confirmed across multiple 2026 RCTs.
2. "Will it extend my life?" — Not demonstrated. No eligible human trial.
3. "Will it make me feel better / perform better?" — Domain-dependent: endurance yes (NMN dose-dependent); subjective fatigue no; strength no; cognitive fatigue maybe (NADH).
4. "IV NAD+?" — No eligible clinical-outcomes trials for anti-aging/wellness. Largely practice-based.